他汀类药物、依折麦布和PCSK9抑制剂的出现极大改善了家族性高胆固醇血症（FH）的预后。然而，尽管进行了最大限度的降脂治疗，许多FH患者的低密度脂蛋白胆固醇（LDL-C）水平仍达不到指南推荐的水平。不依赖于低密度脂蛋白（LDL）受体活性而降低LDL的 ...

该研究表明，PCSK9基因的一种常见种系突变，促进了乳腺癌转移，与患者生存率降低有关。 根据世界卫生组织国际癌症研究机构（IARC）2024年发布的 ...

PCSK9抑制剂的使用正在为临床上难治性高胆固醇血症以及他汀类药物不耐受的患者群体开辟全新的治疗前景。 1月10日，恒瑞医药的一款抗PCSK9药物瑞 ...

At the moment, there is an LNP-based CRISPR-Cas9 candidate treatment for people with heterozygous familial hypercholesterolemia in clinical trials, which targets the PCSK9 gene in the liver.

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.